Consensus Bicycle Therapeutics plc

Stocks

BCYC

US0887861088

Biotechnology & Medical Research

Market Closed - Nasdaq 01:00:00 07/11/2026 +04			5-day change	1st Jan Change
3.610 ^USD	+3.74%		-1.37%	-49.01%

11-03	European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading	MT
10-30	Bicycle Therapeutics Advances Cancer Programs While Keeping Details Close, Oppenheimer Says	MT

Evolution of the Average Target: Bicycle Therapeutics plc

Evolution of the Target Price: Bicycle Therapeutics plc

Changes in Analyst Recommendations: Bicycle Therapeutics plc

69c2.I7qKeUcyItyLBW7C1owPYnikZ2CGzmrFiolfB8ZrilA.aurzLQNbeoTqajmvs85lMxf-Ugv_jwzx68wJNoQq3wJZiek8D3hKlNlfGQ~48085472261559fadae1652572f3f20d

Analysts' recommendations: Bicycle Therapeutics plc

10-30	Bicycle Therapeutics Advances Cancer Programs While Keeping Details Close, Oppenheimer Says	MT
07-31	Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $11 From $36, Maintains Outperform Rating	MT
03-18	Oppenheimer Adjusts Bicycle Therapeutics PT to $36 From $44, Maintains Outperform Rating	MT
03-18	RBC Cuts Price Target on Bicycle Therapeutics to $7 From $11, Keeps Sector Perform, Speculative Risk	MT
31/10/25	RBC Downgrades Bicycle Therapeutics to Sector Perform From Outperform, Cuts Price Target to $11 From $27, Keeps Speculative Risk	MT
11/08/25	Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $44 From $48, Maintains Outperform Rating	MT
11/08/25	RBC Capital Adjusts Price Target on Bicycle Therapeutics to $27 From $25, Maintains Outperform Speculative Risk Rating	MT
17/07/25	RBC Cuts Price Target on Bicycle Therapeutics to $25 From $32, Keeps Outperform, Speculative Risk	MT
02/05/25	RBC Cuts Price Target on Bicycle Therapeutics to $32 From $35, Keeps Outperform, Speculative Risk	MT
16/12/24	B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating	MT
08/11/24	Stephens Starts Bicycle Therapeutics With Equalweight Rating	MT
06/09/24	RBC Initiates Bicycle Therapeutics at Outperform, Speculative Risk With $35 Price Target	MT
07/08/24	B. Riley Downgrades Bicycle Therapeutics to Neutral From Buy, Cuts Price Target to $28 From $33	MT
21/02/24	HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating	MT
20/12/23	JMP Securities Cuts Bicycle Therapeutics Price Target to $32 From $44, Maintains Market Outperform Rating	MT
03/11/23	Morgan Stanley Cuts Price Target on Bicycle Therapeutics to $40 From $42, Maintains Equal-Weight Rating	MT
12/09/23	B. Riley Upgrades Bicycle Therapeutics to Buy From Neutral After Announced Alignment With US FDA on Phase 2/3 Registrational Trial for BT8009 for Metastatic Bladder Cancer; PT is $33	MT
04/08/23	Oppenheimer Adjusts Bicycle Therapeutics Price Target to $48 From $55, Maintains Outperform Rating	MT
04/08/23	JMP Securities Adjusts Price Target on Bicycle Therapeutics to $44 From $46, Maintains Outperform Rating	MT
04/08/23	Needham Adjusts Price Target on Bicycle Therapeutics to $46 From $48, Maintains Buy Rating	MT
05/05/23	Needham Adjusts Price Target on Bicycle Therapeutics to $64 From $67, Maintains Buy Rating	MT
01/03/23	Needham Adjusts Price Target on Bicycle Therapeutics to $67 From $72, Keeps Buy Rating	MT
05/01/23	EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target	MT
09/11/22	JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating	MT
12/09/22	Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BICYCLE THERAPEUTICS PLC					+163.41%
	WUXI APPTEC CO., LTD.					+31%
	ARGENX SE					+22.4%
	LONZA GROUP AG					+4.89%
	IQVIA HOLDINGS INC.					+17.75%
	BEONE MEDICINES AG					+12.99%
	REVOLUTION MEDICINES, INC.					+45.7%
	CELLTRION, INC.					+27.37%
	GENMAB A/S					+10.13%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.84%
	Average					+35.95%
	Weighted average by Cap.					+21.68%